The invention relates to the use of a composition comprising
probiotic bacteria that regulate expression of key components involved in diet-induced
insulin resistance for ameliorating or preventing diet-induced
insulin resistance. The use of the
probiotic strain and / or a fraction of said strain and / or
metabolite of said strain for the manufacture of a medicament or a food or feed product to ameliorate diet-induced
insulin resistance and help to obtain optimal
body weight of a
mammal is disclosed. Preferably, the composition comprises at least one
probiotic Lactobacillus acidophilus strain and / or a fraction of said strain and / or
metabolite of said strain for ameliorating or preventing diet-induced
insulin resistance, said composition characterized by up-regulating expression of the ANGPTL4
gene encoding for FIAF in the intestine, down-regulating expression of the Elovl6
gene in the intestine as well as down-regulating expression of the SCD1
gene in skeletal muscles of a
mammal, and wherein the probiotic strain is selected from the group of strains consisting of
Lactobacillus acidophilus strain LA-5 (DSM13241).